Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
The market is reacted negatively already as if this variant will evade or reduce the efficiency of the vaccines already developed. It is the 30+ mutations on the spike protein that the antibody cannot recognize this variant. This hypothesis needs to be confirmed from the testing and the results should be available in coming weeks.